Kalshi said on Thursday it will introduce markets that permit bets on the outcomes of clinical trials and FDA regulatory reviews, making publicly tradable odds on drug-development events available for the first time on its platform. The new markets are being launched as a pilot in partnership with AppliedXL, a firm that monitors and forecasts clinical trial outcomes.
Kalshi emphasized that these markets are structured to let participants take positions on a single drug program rather than on an entire company. Under the pilot rules, only late-stage clinical trials will be eligible for trading. The exchange will post a contract only after a trial has completed enrollment.
Each contract will settle against a specified, named public document. Examples of the types of documents that will form the basis for contract settlement include the registered primary endpoint on ClinicalTrials.gov, an FDA approval letter, or the recorded vote of an FDA advisory committee. AppliedXL will set and publish the criteria used to interpret those documents before a contract opens for trading, rather than after results are released.
Kalshi said contracts available at launch include more than a dozen FDA decisions. Among the settlement events listed are whether the agency will approve Gilead's experimental cancer therapy anito-cel and whether it will approve Summit Therapeutics' experimental lung cancer therapy ivonescimab. Another market will address whether a late-stage trial of an early Alzheimer's disease drug developed by AriBio will meet its pre-specified primary goals.
The platform will impose identity and employment checks on prospective traders. Kalshi will require employment verification from all participants and will prohibit trading by anyone who possesses material nonpublic information related to the contracts.
Launched in 2021, Kalshi previously offered markets on topics ranging from sports and elections to weather. The company is now extending its scope to regulated drug-development outcomes through this partnership with AppliedXL, which will also provide the pre-defined criteria used to read and interpret the public documents that determine contract settlement.
Summary
Kalshi is adding pilot markets for late-stage clinical trials and FDA decisions in collaboration with AppliedXL. Contracts will only be listed after trials finish enrolling and will settle against named public documents, with AppliedXL defining the interpretive criteria ahead of trading. The platform will require employment verification and bar traders with material nonpublic information.
Key points
- Markets will cover outcomes of late-stage clinical trials and FDA regulatory rulings, allowing wagers on single-drug events rather than whole companies.
- Contracts are listed only after trial enrollment completes and will settle on specified public documents such as ClinicalTrials.gov endpoints, FDA approval letters, or advisory committee votes; AppliedXL sets the settlement criteria before trading opens.
- Kalshi requires employment verification for traders and prohibits trading by those who hold material nonpublic information.
Risks and uncertainties
- The pilot limits eligible events to late-stage trials, which constrains the scope of tradable outcomes and may delay the availability of some contracts - this affects market participants interested in earlier-stage development outcomes.
- Contracts rely on interpretation of named public documents; while AppliedXL will set criteria in advance, disputes or ambiguities in public records could affect settlement clarity and timing - this impacts biotech and healthcare-focused traders and funds.
- Compliance controls such as employment verification and prohibitions on trading by insiders are intended to limit access by those with material nonpublic information, but enforcement and monitoring will determine their effectiveness and could influence participation levels from industry employees.
Note: This report is based solely on the information provided about the new Kalshi markets and the partnership with AppliedXL. No additional claims or projections are made beyond the facts presented.